News

• ProSyntest will become Cambrex Tallinn, a member of Cambrex Corporation family. ProSyntest is pleased to announce that Cambrex Karlskoga AB, a subsidiary of Cambrex Corporation (NYSE: CBM) has entered into a purchase agreement for of ProSyntest AS. The business will be renamed Cambrex Tallinn after completion of the acquisition. Cambrex Tallinn intends to add more process and analytical chemists at the site and continue early API development work and co-operate actively with other partners of the Corporation: Cambrex Karlskoga, Sweden, Cambrex North Brunswick, USA, Cambrex Charles City, USA, Cambrex Profarmaco Milano (Italy). “ProSyntest, located in Eastern Europe, will enable Cambrex to more effectively compete in the high growth early clinical stage pharmaceutical custom development market and provide us with a strong pool of talented chemists to advance numerous proprietary strategic initiatives," commented Steven Klosk, Executive Vice President & COO of Cambrex Corporation.

  About ProSyntest

  ProSyntest was formed in 1990 as a spin off from Tallinn University of Technology. It has strengths in cost effective chemical route selection and sample generation, rapid scale up of products at kilo lab scale, as well as chiral and organometallic chemistries. At present ProSyntest employs twenty five chemists located within the Tallinn Technology Park in Tallinn, Estonia. For more information, please visit www.prosyntest.com.

  About Cambrex

  Cambrex provides products and services to accelerate the development and commercialization of small molecule active pharmaceutical ingredients ("APIs"), advanced intermediates and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit www.cambrex.com.



• 2-methyl-5-oxotetrahydrofuran-2-carboxylic acid is now available. ProSyntest announces the availability of the 2-methyl-5-oxotetrahydrofuran-2-carboxylic acid. Both the S & R isomers of this unique building block are offered. Please visit our products section for an additional data.



• Competence Centre for Cancer Research (CCCR) receives funding. Foundation Enterprise Estonia has made a positive decision about the funding of an application of CCCR. ProSyntest, being a member of CCCR, therefore secures additional support for its anticancer-oriented development project "Bioactive Analogs of Nucleosides" from the centre.



• (R)-(-)-2-carboxytetrahydro-5-oxo-2-furanacetic acid is available. The (R)-Homocitric acid lactone ( (R)-(-)-2-carboxytetrahydro-5-oxo-2-furanacetic acid ) was recently added to our products list. For more information please visit our products section.